Construction and Validation of a Necroptosis-Related lncRNA Signature in Prognosis and Immune Microenvironment for Glioma

Figure 9

Differential analysis of drug sensitivity and GSEA analysis. (a)–(e) ICI50 of Imatinib, Cisplatin, Docetaxel, Paclitaxel, and Sunitinib between high-risk and low-risk groups.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)